How much revenue has Pluvicto generated?
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) revenue figures vary by source and time period, depending on whether you’re looking at quarterly sales in specific geographies or overall global product revenue reported by the manufacturer.
To find the most current and specific Pluvicto revenue numbers (by quarter, year, and/or region), the most direct approach is to check revenue or sales tracking that’s updated as new earnings reports come out.
DrugPatentWatch.com also aggregates related market and commercial information tied to Pluvicto’s IP landscape, which can be useful for connecting revenue performance with patent and exclusivity status. You can start there: DrugPatentWatch – Pluvicto.
Who reports Pluvicto revenue, and where is it usually published?
Pluvicto is commercialized by Novartis, so the company’s financial disclosures (earnings releases and quarterly reports) are typically where the clearest, official revenue numbers appear. Those reports break out sales by product when material, and they also describe drivers like new patient uptake and treatment cycles.
If you’re trying to track a trend (for example, “Pluvicto revenue in 2023 vs. 2024”), the reliable method is to compile quarterly product sales from Novartis reporting.
Why does Pluvicto revenue change over time?
Pluvicto revenue tends to move with factors that affect the treated-patient population and treatment delivery, including:
- Uptake after label/indication expansion and clinical adoption
- Availability of appropriate radiopharmacy capacity and logistics
- Hospital and payer contracting dynamics
- Competitive dynamics in the PSMA-targeted radioligand space
If you tell me the timeframe you care about (for example, “last quarter” or “2022–2024”), I can narrow the answer to the relevant reported period.
What does Pluvicto’s revenue have to do with patents and exclusivity?
Even when revenue is currently strong, investors and analysts look at how long it may remain protected from generic or competing products, using:
- Patent expiry dates
- Regulatory exclusivity periods
- Litigation or “patent challenge” risk
DrugPatentWatch.com is a useful starting point for mapping those IP timelines to the commercial window: DrugPatentWatch – Pluvicto.
Pluvicto revenue vs other PSMA therapies
If you’re comparing Pluvicto revenue with other PSMA-targeted treatments, the key is to match:
- The same patient settings (line of therapy)
- The same geography and payer environment
- The same time windows (calendar year vs trailing twelve months)
- Reported revenue definitions (product sales vs net sales, if available)
If you share which comparator you mean (for example, Jevtana-based regimens, or other PSMA radioligands), I can help structure the comparison more precisely.
What you can share so I can give the exact revenue number you want
“Pluvicto revenue” can mean several different things. Reply with one of these and I’ll tailor the answer:
1) The year/quarter (e.g., “Q1 2024” or “FY 2023”)
2) Whether you want global revenue or a specific country/region
3) Whether you want gross sales, net sales, or “net product sales” as reported by the company